Silver Book

Silver Book Fact

Disease specific status and generic health status improvements from TAVR and SAVR

Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to 22 point improvement on a 100 point scale) and in generic health status (3.9 to 5.1 point improvement on a 36 point scale).

Baron S, Arnold S, Wang K, et al. Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Risk: Results from PARTNER 2 Randomized Clinical Trial. JAMA Cardiology. 2017; 2(8): 837-45. https://jamanetwork.com/journals/jamacardiology/article-abstract/2635358

Reference

Title
Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Risk: Results from PARTNER 2 Randomized Clinical Trial
Publication
JAMA Cardiology
Publication Date
2017
Authors
Baron S, Arnold S, Wang K, et al
Volume & Issue
Volume 2, Issue 8
Pages
837-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Publications

Aortic Stenosis Fact Sheet

 https://www.silverbook.org/wp-content/uploads/2017/10/AS-FS-cover.png Thumbnail

Related Facts

  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • Survival Rates of SAS Patients with and without SAVR
    Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
  • Survival rates of SAS patients ages 80+ with and without SAVR
     
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).